Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Share

.2024 Aug 20;14(1):19305.
doi: 10.1038/s41598-024-69778-6.

MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas

Affiliations

MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas

Carla Chizuru Tajima et al. Sci Rep..

Abstract

To compare the magnetic resonance imaging (MRI) features of different immunophenotypes of breast carcinoma of no special type (NST), with special attention to estrogen receptor (ER)-low-positive breast cancer. This retrospective, single-centre, Institutional Review Board (IRB)-approved study included 398 patients with invasive breast carcinoma. Breast carcinomas were classified as ER-low-positive when there was ER staining in 1-10% of tumour cells. Pretreatment MRI was reviewed to assess the tumour imaging features according to the 5th edition of the Breast Imaging Reporting and Data System (BI-RADS) lexicon. Of the 398 cases, 50 (12.6%) were luminal A, 191 (48.0%) were luminal B, 26 (6.5%) were luminal ER-low positive, 64 (16.1%) were HER2-overexpressing, and 67 (16.8%) were triple negative. Correlation analysis between MRI features and tumour immunophenotype showed statistically significant differences in mass shape, margins, internal enhancement and the delayed phase of the kinetic curve. An oval or round shape and rim enhancement were most frequently observed in triple-negative and luminal ER-low-positive tumours. Spiculated margins were most common in luminal A and luminal B tumours. A persistent kinetic curve was more frequent in luminal A tumours, while a washout curve was more common in the triple-negative, HER2-overexpressing and luminal ER-low-positive immunophenotypes. Multinomial regression analysis showed that luminal ER-low-positive tumours had similar results to triple-negative tumours for almost all variables. Luminal ER-low-positive tumours present with similar MRI findings to triple-negative tumours, which suggests that MRI can play a fundamental role in adequate radiopathological correlation and therapeutic planning in these patients.

Keywords: Breast cancer; Estrogen receptors; Magnetic resonance imaging; Triple-negative breast neoplasms.

© 2024. The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flowchart of inclusion and exclusion criteria for the study.
Figure 2
Figure 2
Irregular unifocal mass with spiculated margins in the left breast. IHC: Luminal A (ER 90%, PgR 90%, HER2 -, Ki67 10%).
Figure 3
Figure 3
Irregular mass in the left breast (circle) with a satellite mass (thin arrow) and associated NME (thick arrow). IHC: Luminal B subtype (ER 95%, PgR 70%, HER2 -, Ki67 40%).
Figure 4
Figure 4
Round unifocal mass in the left breast. IHC: Luminal ER-low-positive (ER 5%, PgR -, HER2 -, Ki67 90%).
Figure 5
Figure 5
Multiple correspondence analysis (MCA) of MRI features and immunophenotypes of NST invasive breast carcinomas.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Giuliano, A. E. et al. Breast cancer-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin.67, 290–303. 10.3322/caac.21393 (2017). 10.3322/caac.21393 - DOI - PubMed
    1. Kalli, S. et al. American joint committee on cancer’s staging system for breast cancer, eighth edition: What the radiologist needs to know. Radiographics38, 1921–1933. 10.1148/rg.2018180056 (2018). 10.1148/rg.2018180056 - DOI - PubMed
    1. Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J. Clin. Oncol.38, 1346–1366. 10.1200/jco.19.02309 (2020). 10.1200/jco.19.02309 - DOI - PubMed
    1. Yi, M. et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann. Oncol.25, 1004–1011. 10.1093/annonc/mdu053 (2014). 10.1093/annonc/mdu053 - DOI - PMC - PubMed
    1. Rajc, J., Fröhlich, I., Mrčela, M., Tomaš, I. & Flam, J. Prognostic impact of low estrogen and progesterone positivity in luminal B (Her2 negative) breast cancer. Acta Clin. Croat.57, 425–433. 10.20471/acc.2018.57.03.04 (2018). 10.20471/acc.2018.57.03.04 - DOI - PMC - PubMed

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp